Navigation Links
Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
Date:10/25/2007

can Society of Hematology (ASH) in December 2007.

- The Genasense study is the only randomized controlled trial ever

conducted in this population.

- The number, type, and severity of adverse reactions encountered with

Genasense were comparable to other leukemia drugs, which are readily

managed by specialists.

Genasense in CLL

In the pivotal Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive fludarabine plus cyclophosphamide (Flu/Cy) chemotherapy with or without Genasense. This trial - the first randomized study ever conducted in this population - achieved its primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR/nPR) (17% vs. 7%; P=0.025). In addition, the duration of CR/nPR was significantly longer for patients treated with Genasense (median = not reached but exceeding 36 months in the Genasense group vs. 22 months for patients treated with chemotherapy alone).

Prior to randomization on this trial, patients were prospectively stratified according to criteria that reflected their responsiveness to prior chemotherapy. The CR/nPR response to Flu/Cy alone was both equally poor (6-7%) and numerically inferior in all stratification groups. Clear trends, evident across all strata, suggested that the best response to Genasense occurred in patients who had received less extensive therapy. In addition to achieving the prospectively defined, intent-to-treat primary endpoint, patients in the Genasense group who were protocol-defined as "non-refractory" to fludarabine (comprising more than 40% of the total population) achieved:

- A four-fold increase in CR/nPR (25% [13/51] vs. 6% [3/50]; P = 0.016)

- Increased time-to-progression (median = 12 months. vs. 10 months;

P = N.S.)

- Increased overall survival (median not reached but exceeding 39 months.

vs. 33
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sonic Foundry completes $11.25M stock offer
2. Orion Energy completes $5M capital round
3. RedPrairie completes MARC acquisition
4. Metavante completes purchase of check processing firm
5. GE completes $1.2 billion acquisition
6. M & Is Metavante completes Brasfield Corp. acquisition
7. Metavante completes GHR Systems acquisition
8. Metavante completes TREEV acquisition
9. Johnson Controls completes sale of French unit
10. OpGen completes $5 million investment round
11. UW Hospital completes deployment of error-reducing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)...   Ceres, Inc . (Nasdaq: CERE ... financial results for the three months ended May 31, ... Ceres reported that the company and its customers ... season in Brazil, which concluded in June, despite dry ... areas for part of the growing season. Yields of ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... are today,s highlights from the AACE Annual Meeting & Clinical Congress in Boston : ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b ) , ... Research Shows First-of-Its-Kind Hydrogel Decreases Obese Patients, Desire for Food   , ... New research indicates that a first-of-its-kind, superabsorbent hydrogel significantly increased the post-meal ...
... NEW YORK and SCOTTSDALE, Ariz. , ... Amex: NBS ), an international biopharmaceutical,company with operations ... BioSciences,Inc., a wholly owned subsidiary of IR BioSciences Holdings, ... entered into a,Collaborative Research Agreement, focused on the development ...
... ... Biotechnology Companies , ... Rochester, New York (PRWEB) April 22, 2010 -- iCardiac Technologies, Inc., a provider of ... has awarded iCardiac a cardiac safety study leveraging iCardiac’s COMPAS technology platform including advanced ...
Cached Biology Technology:Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress 2Thursday News Highlights from the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress 3NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 2NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 3NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 4NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 5NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 6NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 7Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
(Date:7/11/2014)... The University of Chicago is creating a new ... at the University,s Institute for Molecular Engineering and ... million donation from the Millicent and Eugene Bell ... will reside within the Institute for Molecular Engineering. ... research project at the MBL,s Eugene Bell Center ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... July 11, 2014 The increased risk of kidney ... in resuscitation fluids reflects the mass of HES molecules, ... , official journal of the International Anesthesia Research Society ... the harmful effect of HES on cultured human renal ... Dr Christian Wunder and colleagues of University Hospital Wrzburg, ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... The first analysis of the healthful antioxidant content ... South America concludes that some of these fruits have ... renowned as "super fruits" sold throughout the United ... protection against heart disease, cancer and other conditions, the ...
... not rely on oxygen may have played an important role ... a theory that UChicago researcher Albert Colman is testing in ... He has found that bacteria at the site produce ... scientists must take into account as they attempt to reconstruct ...
... Planes were grounded all over Europe when the Eyjafjallajkull volcano erupted ... fly zone was really necessary. And the only way to find ... cloud - a potentially fatal experiment. , Now a team ... Iceland have developed a protocol for rapidly providing air traffic authorities ...
Cached Biology News:Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3Novel ash analysis validates volcano no-fly zones 2
...
...
... Anti-β-Tubulin IV Recognizes an epitope ... of β-tubulin isotype IV. No ... is observed. ascites fluid synthetic ... sequence of β-tubulin isotype IV, ...
... Finnpipette BioControl is a major step ... complete liquid handling system - with ... tip cone modules. All five single ... modules fit one handle. The lightweight ...
Biology Products: